Keymed Biosciences anuncia la aprobación de CM518D1 para el tratamiento de tumores sólidos ...Middle East

Keymed Biosciences anuncia la aprobación de IND para CM518D1 por parte de la Administración Nacional de Productos Médicos de China para el tratamiento de tumores sólidos CHENGDU, China, 27 de abril de 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" o la "compañía")...

Hence then, the article about keymed biosciences anuncia la aprobacion de cm518d1 para el tratamiento de tumores solidos was published today ( Sunday 27/04/2025 - 08:34 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Keymed Biosciences anuncia la aprobación de CM518D1 para el tratamiento de tumores sólidos )

Also on site :

• Nazi salutes and drug cartels: Dutch mercenary recounts service with Kiev’s military
• Macy’s Valley Fair shoppers thwart Rolex watch thieves
• Allegiant and Sun Country Airlines to Combine, Creating a Leading, More Competitive Leisure-Focused U.S. Airline